Opinion

Video

Dr Hanna & Hope Rugo, MD Shares Potential Role of Improving Access to CDK4/6 Inhibitors

Drs. Hanna and Rugo discuss possible access improvements in regards to CDK4/6 inhibitors.

Video content above is prompted by the following question(s):

  • What is the potential role of value-based pricing models or alternative payment arrangements in improving access to CDK4/6 inhibitors for eligible patients?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Videos
Michael Hassett, MD, MPH, Dana-Farber Cancer Institute
Rebecca Chacko, MD.
Rebecca Chacko, MD, breast medical oncologist at Henry Ford
4 experts in this video
4 experts in this video
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo